Recruiting
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Genmab A/S· Source
Recruiting
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· Phase 3· Unicancer· Source
Recruiting
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845· Phase 2· AbbVie· Source
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source
Recruiting
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· Phase 2· UNICANCER· Source
Recruiting
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· Phase 2/3· Eikon Therapeutics· Source
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· Phase 3· UNICANCER· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Active, not recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· Phase 3· Celcuity Inc· Source
Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· Phase 3· UNICANCER· Source
Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05255653· Phase 3· Leiden University Medical Center· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Completed
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· Phase 3· UNICANCER· Source
Active, not recruiting
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516· Phase 3· Aragon Pharmaceuticals, Inc.· Source